Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol

Among men with high-risk non-metastatic prostate cancer, combination therapy is associated
with significantly higher rates of metastasis-free survival compared with ADT alone.
Abiraterone acetate with prednisolone should be considered a new standard treatment
for this population.